Banque Pictet & Cie 13F: Adds $27M to AstraZeneca (AZN) Stake

Banque Pictet & Cie disclosed in a filing on October 16, 2026, that it increased its stake in AstraZeneca PLC (NYSE: AZN) by 163,549 shares. This boost brought the total holdings to 350,235 shares, valued at approximately $57.1 million. This increase represents an 87.6% change in its position.

What Changed in Banque Pictet & Cie's AstraZeneca Position

The firm added 163,549 shares to its holdings, growing its position from 186,686 shares to 350,235 shares. This significant increase shows Banque Pictet & Cie's commitment to AstraZeneca as part of its portfolio strategy.

Other Institutional Activity in AstraZeneca

Investor AB holds 51,587,810 shares of AstraZeneca, valued at about $8.5 billion. Vanguard Capital Management LLC increased its stake by 346,803 shares, bringing its total to 45,386,190 shares worth approximately $7.5 billion. Capital International Investors added 182,287 shares, now holding 34,576,070 shares valued at around $5.7 billion. NORGES BANK raised its stake significantly by 33,226,081 shares, totaling 33,864,172 shares valued at approximately $5.6 billion. Capital World Investors grew its holdings by 1,811,687 shares, ending with 30,075,134 shares worth about $4.9 billion.

AstraZeneca PLC Stock Holds Steady

As of October 16, 2026, AstraZeneca shares recently traded around $166.71. This price is below the stock's 50-day moving average of $162.05 but above its 52-week low of $153.41. However, it's about 21.6% below the stock's 52-week high of $212.71, indicating potential for growth as it remains below the average analyst price target of $207.16.

Recent Earnings

In its latest financials, AstraZeneca reported a trailing twelve-month revenue of approximately $61.4 billion, with a net margin of 17.0% and a return on equity of 22.0%. The company is scheduled to report its next earnings on October 30, 2026, which investors will be keen to watch for further updates.

Insider Buying and Selling at AstraZeneca PLC

This absence of insider trading activity suggests that management may be maintaining their current positions without any alterations.

Analysts Set New Price Targets

On August 24, 2026, CICC initiated coverage on AstraZeneca with an "Outperform" rating and set a price target of $198.00. The consensus from analysts is a "buy" with a mean price target of $207.16 based on various evaluations of the stock's potential.

About AstraZeneca

AstraZeneca PLC is a biopharmaceutical company headquartered in Cambridge, United Kingdom. It focuses on developing, manufacturing, and commercializing prescription medicines, mainly in the areas of oncology, cardiovascular, renal, and respiratory diseases. The recent increase in Banque Pictet's stake illustrates confidence in AstraZeneca's ongoing growth and strategic direction.

Bottom Line

Investors should look out for AstraZeneca's upcoming earnings report on October 30, 2026, as it may offer insights into the company's performance and market outlook. Remember that the holdings reflected in Banque Pictet's filing are as of this date and may not represent its current position.